BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 36701998)

  • 1. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
    Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
    Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of local immunogenic cell death-inducing chemotherapy and DNA vaccine increases the survival of glioblastoma-bearing mice.
    Bausart M; Rodella G; Dumont M; Ucakar B; Vanvarenberg K; Malfanti A; Préat V
    Nanomedicine; 2023 Jun; 50():102681. PubMed ID: 37105343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma.
    Li TF; Li K; Zhang Q; Wang C; Yue Y; Chen Z; Yuan SJ; Liu X; Wen Y; Han M; Komatsu N; Xu YH; Zhao L; Chen X
    Biomaterials; 2018 Oct; 181():35-52. PubMed ID: 30071380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
    Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
    J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of Bio-Responsive Hyaluronic Acid-Doxorubicin Conjugates for the Local Treatment of Glioblastoma.
    Malfanti A; Catania G; Degros Q; Wang M; Bausart M; Préat V
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.
    Kadiyala P; Li D; Nuñez FM; Altshuler D; Doherty R; Kuai R; Yu M; Kamran N; Edwards M; Moon JJ; Lowenstein PR; Castro MG; Schwendeman A
    ACS Nano; 2019 Feb; 13(2):1365-1384. PubMed ID: 30721028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Microenvironment-Triggered Charge Reversal Polymetformin-Based Nanosystem Co-Delivered Doxorubicin and IL-12 Cytokine Gene for Chemo-Gene Combination Therapy on Metastatic Breast Cancer.
    Sun Y; Liu L; Zhou L; Yu S; Lan Y; Liang Q; Liu J; Cao A; Liu Y
    ACS Appl Mater Interfaces; 2020 Oct; 12(41):45873-45890. PubMed ID: 32924511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
    Zang X; Song J; Yi X; Piyu J
    J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythrocyte membrane-camouflaged DNA-functionalized upconversion nanoparticles for tumor-targeted chemotherapy and immunotherapy.
    Kou Q; Huang Y; Su Y; Lu L; Li X; Jiang H; Huang R; Li J; Nie X
    Nanoscale; 2023 Jun; 15(21):9457-9476. PubMed ID: 37161583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transformable prodrug nanoplatform
    Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
    Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostimulant In Situ Fibrin Gel for Post-operative Glioblastoma Treatment by Macrophage Reprogramming and Photo-Chemo-Immunotherapy.
    Zhang R; Ye Y; Wu J; Gao J; Huang W; Qin H; Tian H; Han M; Zhao B; Sun Z; Chen X; Dong X; Liu K; Liu C; Tu Y; Zhao S
    ACS Appl Mater Interfaces; 2023 Apr; 15(14):17627-17640. PubMed ID: 37000897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-Assembled Immunostimulatory Tetrahedral Framework Nucleic Acid Vehicles for Tumor Chemo-immunotherapy.
    Liu M; Hao L; Zhao D; Li J; Lin Y
    ACS Appl Mater Interfaces; 2022 Aug; 14(34):38506-38514. PubMed ID: 35973112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
    Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
    Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
    Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
    ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer.
    Vogus DR; Evans MA; Pusuluri A; Barajas A; Zhang M; Krishnan V; Nowak M; Menegatti S; Helgeson ME; Squires TM; Mitragotri S
    J Control Release; 2017 Dec; 267():191-202. PubMed ID: 28823957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment.
    Yang M; Wang B; Yin Y; Ma X; Tang L; Zhang Y; Fan Q; Yin T; Wang Y
    J Control Release; 2023 Jan; 353():63-76. PubMed ID: 36402232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound-mediated delivery of flexibility-tunable polymer drug conjugates for treating glioblastoma.
    Sun T; Krishnan V; Pan DC; Filippov SK; Ravid S; Sarode A; Kim J; Zhang Y; Power C; Aday S; Guo J; Karp JM; McDannold NJ; Mitragotri SS
    Bioeng Transl Med; 2023 Mar; 8(2):e10408. PubMed ID: 36925708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.